FuturHealth Review
Best for: pending product verification
FuturHealth is a telehealth weight management brand offering prescription weight loss medications including GLP-1 therapy. Listed in the Katalys catalog at program ID 815 with a $180 default CPA. Stub entry pending YMYL verification — exact drug formulary, pricing, states served, and pharmacy partners need a primary-source pass against the brand website.
Low confidence · Last verified 2026-04-09 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
FuturHealth is a solid telehealth option with balanced features and pricing.
Score Breakdown
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Preliminary | compounded | $199 |
✓ Pros
- •Katalys-approved program at $180 default CPA — non-trivial commission
- •Explicitly positioned around weight loss medication (not a general telehealth catch-all)
✗ Cons
- •Stub entry — exact drug formulary, pricing tiers, states served, and pharmacy partners need a YMYL verification pass
- •Confidence is LOW until that pass is done
- •Domain not yet verified — futurhealth.com may not be the correct landing page
Ready to start with FuturHealth?
Starting at $199/month. See current pricing and start your free consultation.
Sources & methodology
Our FuturHealth review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
Alternatives to FuturHealth
Editorial score · methodology
Amazon Pharmacy
Best for: fastest brand-name Foundayo delivery with the cheapest insured price
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Ready to start with FuturHealth?
Starting at $199/month. See current pricing and start your free consultation.